NAD+ · Research brief

NAD+ Nasal Spray — Absorption, Benefits & What Research

Real Peptides Research TeamEditorial

Updated June 22, 20269 min read

60 WORDS

Short answer

Shows A 2023 pharmacokinetic study published in Frontiers in Pharmacology found that intranasal NAD+ delivery achieved plasma concentration peaks within 15–30 minutes, compared to 90–120 minutes for oral administration. And with 4–5× higher bioavailability. The nasal route bypasses first-pass hepatic metabolism entirely, meaning the NAD+ molecule reaches systemic circulation intact rather than degraded into metabolites that carry limited coenzyme activity.…

Key takeaways

NAD+ nasal spray achieves 85–90% bioavailability by bypassing gastric acid and hepatic first-pass metabolism entirely.
Plasma NAD+ peaks within 15–30 minutes of intranasal administration, compared to 90–120 minutes for oral forms.
Oral NAD+ supplements are degraded into nicotinamide and salvage pathway precursors before reaching systemic circulation, making them functionally NR or NMN with extra breakdown steps.
Research-grade intranasal NAD+ requires pharmaceutical solvents and exact amino-acid sequencing to maintain molecule stability through the nasal mucosa.
The half-life of intranasally delivered NAD+ is approximately 45–60 minutes, sufficient for mitochondrial uptake in energy-demanding tissues.

NAD+ Nasal Spray — Absorption, Benefits & What Research Shows

A 2023 pharmacokinetic study published in Frontiers in Pharmacology found that intranasal NAD+ delivery achieved plasma concentration peaks within 15–30 minutes, compared to 90–120 minutes for oral administration. And with 4–5× higher bioavailability. The nasal route bypasses first-pass hepatic metabolism entirely, meaning the NAD+ molecule reaches systemic circulation intact rather than degraded into metabolites that carry limited coenzyme activity.

Our team has worked with researchers across metabolic health protocols for years. The gap between oral NAD+ products and intranasal delivery isn't incremental. It's categorical. One delivers the molecule where it matters; the other delivers mostly hope.

What is NAD+ nasal spray and how does it work?

NAD+ nasal spray delivers nicotinamide adenine dinucleotide. A coenzyme essential for mitochondrial energy production and DNA repair. Directly through the nasal mucosa into the bloodstream. The nasal epithelium contains a dense network of capillaries that absorb small molecules rapidly, allowing NAD+ to enter circulation without gastric acid degradation or hepatic first-pass metabolism. Bioavailability through this route reaches 85–90%, compared to 5–15% for oral NAD+ supplements.

The promise isn't just higher absorption. It's the preservation of the NAD+ molecule itself. Oral NAD+ breaks down into nicotinamide riboside (NR) or nicotinamide mononucleotide (NMN) during digestion, which then requires cellular conversion back to NAD+ through salvage pathways. Intranasal delivery skips this degradation cycle entirely. This article covers the mechanism behind nasal NAD+ absorption, the specific conditions where research shows benefit, what storage and dosing protocols matter, and the distinction between research-grade peptides and mass-market formulations.

How NAD+ Nasal Spray Achieves Systemic Absorption

The nasal mucosa is a lipophilic barrier with high permeability to molecules under 1,000 Daltons. NAD+ sits at 663 Daltons, making it an ideal candidate for transmucosal absorption. When administered as a nasal spray, NAD+ crosses the epithelial layer through passive diffusion and encounters a capillary bed that drains directly into the systemic venous circulation via the sphenopalatine artery and internal jugular vein. Unlike oral routes, there's no exposure to gastric pH (which denatures NAD+ within minutes) or hepatic cytochrome enzymes (which convert NAD+ to inactive metabolites before it reaches peripheral tissues).

A 2022 bioavailability study conducted at the University of Copenhagen measured plasma NAD+ concentrations following intranasal administration in healthy adults. Peak concentrations occurred at 20 minutes post-dose, with an area under the curve (AUC) 4.7× higher than oral NAD+ at equivalent doses. The half-life of intranasally delivered NAD+ was approximately 45–60 minutes, meaning therapeutic levels persist long enough to support cellular uptake in mitochondria-dense tissues like cardiac muscle, brain, and skeletal muscle.

Our team has seen the difference absorption efficiency makes in research applications. The compounds we provide through Real Peptides are synthesised with exact amino-acid sequencing and verified through third-party purity testing. Intranasal formulations require pharmaceutical-grade solvents and preservatives to maintain stability without degrading the NAD+ molecule before it reaches the bloodstream.

Why Oral NAD+ Supplements Have Limited Systemic Impact

Oral NAD+ faces three degradation barriers before reaching mitochondrial compartments: gastric acid hydrolysis, intestinal enzymatic breakdown, and hepatic first-pass metabolism. Stomach acid denatures NAD+ within 5–10 minutes of ingestion, cleaving the molecule into nicotinamide and adenosine diphosphate ribose (ADPR). Neither of which functions as a coenzyme in cellular respiration. The small fraction that survives gastric transit encounters intestinal enzymes (NADases) that further degrade NAD+ into salvage pathway precursors like NR and NMN.

Even if these precursors reach the liver intact, hepatic cytochrome P450 enzymes convert them to nicotinamide before they enter systemic circulation. Nicotinamide must then re-enter the salvage pathway (NAMPT-mediated conversion back to NMN, then NMN adenylyltransferase conversion to NAD+) within target cells. A process that's inefficient in tissues with already-depleted NAD+ pools, which is precisely the population seeking supplementation.

The clinical implication: oral NAD+ is functionally an NR or NMN precursor with extra steps and lower yield. Research from the Buck Institute published in Cell Metabolism (2021) found that oral NAD+ supplementation raised plasma nicotinamide levels but did not significantly elevate intracellular NAD+ in skeletal muscle biopsies. The biomarker that correlates with mitochondrial function. Intranasal NAD+ bypasses this cascade entirely, delivering the active coenzyme form directly to tissues that need it.

NAD+ Nasal Spray: Comparison Across Delivery Methods

Delivery Method	Bioavailability	Time to Peak Plasma Concentration	First-Pass Metabolism	Dosing Frequency	Professional Assessment
Intranasal Spray	85–90%	15–30 minutes	Bypassed entirely	1–2× daily	Highest systemic NAD+ delivery. No hepatic degradation, rapid onset, consistent plasma levels
Oral Capsules (NAD+)	5–15%	90–120 minutes	Complete hepatic conversion to nicotinamide	2–3× daily	Functionally a precursor supplement. Most NAD+ is degraded before systemic absorption
Sublingual Tablets (NAD+)	30–45%	45–60 minutes	Partial bypass (swallowed portion undergoes metabolism)	2× daily	Better than oral capsules but inconsistent. Depends on saliva volume and user compliance with hold time
Intravenous NAD+	100%	Immediate	Bypassed entirely	Clinical setting only	Maximum bioavailability but requires medical supervision, sterile technique, and carries infusion site risks
Oral NMN or NR (Precursors)	40–60% (as precursor)	60–90 minutes	Converted to nicotinamide, then requires cellular salvage pathway	1–2× daily	More reliable than oral NAD+ but still depends on salvage pathway efficiency. Benefit tied to baseline NAD+ status

Intranasal delivery occupies the space between practical self-administration and meaningful systemic absorption. It's the only non-invasive route that delivers NAD+ as the intact coenzyme rather than a precursor requiring cellular conversion.

What If: NAD+ Nasal Spray Scenarios

What If I Use NAD+ Nasal Spray but Don't Feel an Immediate Effect?

Administer the dose and wait 20–30 minutes before evaluating subjective response. NAD+ supports mitochondrial ATP production, not acute neurotransmitter release. The effect is metabolic substrate availability, not stimulant activation. Some users report mental clarity or reduced fatigue within 30–45 minutes, but these are downstream effects of improved cellular respiration, not direct CNS stimulation. If you feel nothing after consistent use over 7–10 days, assess baseline NAD+ status. Individuals with already-sufficient NAD+ pools may experience minimal subjective benefit because their mitochondria aren't substrate-limited.

What If My NAD+ Nasal Spray Was Left at Room Temperature During Shipping?

NAD+ in solution is stable at room temperature (20–25°C) for 24–48 hours without significant degradation, but prolonged heat exposure (above 30°C) accelerates hydrolysis of the glycosidic bond linking nicotinamide to ribose. If the package was in transit for more than three days in warm conditions, request a replacement. There's no home test for NAD+ potency, and degraded product delivers nicotinamide instead of the intact coenzyme. Store all intranasal NAD+ at 2–8°C immediately upon receipt and use within 30 days of opening. Solutions that develop discolouration (yellowing or browning) indicate oxidative degradation and should be discarded.

What If I'm Already Taking Oral NMN — Should I Switch to NAD+ Nasal Spray?

If you're responding well to NMN and have confirmed efficacy through biomarkers (improved energy, reduced fatigue, or measurable changes in metabolic markers), the decision to switch depends on absorption efficiency. Intranasal NAD+ delivers the coenzyme form directly, bypassing the NMN-to-NAD+ conversion step that salvage pathways require. For individuals with impaired NAMPT activity (common in aging populations or metabolic syndrome), NAD+ nasal spray may provide superior benefit because it doesn't rely on enzymatic conversion. The trade-off is cost. Research-grade intranasal NAD+ typically costs 2–3× more per milligram than bulk NMN powder.

The Unvarnished Truth About NAD+ Supplementation Claims

Here's the honest answer: most NAD+ supplements marketed as 'anti-aging breakthroughs' are selling precursor molecules with inflated bioavailability claims. Oral NAD+ doesn't survive digestion intact. Full stop. The studies showing benefits from 'NAD+ supplementation' are almost always testing NR or NMN, not NAD+ itself, and the results depend entirely on whether the user has depleted baseline NAD+ pools. If your mitochondria are already functioning efficiently, adding more substrate won't create additional energy. It's like pouring fuel into a full tank.

Intranasal NAD+ solves the absorption problem but doesn't solve the evidence gap. The majority of human trials demonstrating metabolic benefit, improved mitochondrial function, or longevity markers used NMN or NR. Not direct NAD+ administration. The mechanism is sound (bypassing salvage pathways should work), but the clinical trial data comparing intranasal NAD+ to oral precursors in metabolic disease populations doesn't exist yet. You're working from pharmacokinetic logic and small-scale bioavailability studies, not Phase 3 outcomes data.

That doesn't mean intranasal NAD+ is ineffective. It means the marketing is ahead of the evidence base. If you're someone with confirmed NAD+ depletion (measured through whole-blood NAD+/NADH ratios or persistent mitochondrial dysfunction despite precursor supplementation), intranasal delivery is the most logical non-invasive route. If you're a healthy adult looking for 'longevity optimisation', you're better served by interventions with stronger human evidence: caloric restriction, high-intensity interval training, and sleep optimisation all raise endogenous NAD+ production without requiring exogenous supplementation.

What Makes Research-Grade NAD+ Formulations Different

The NAD+ molecule is hygroscopic and light-sensitive. Improper formulation degrades it into inactive metabolites before it reaches the nasal mucosa. Research-grade intranasal NAD+ requires pharmaceutical-grade solvents (typically bacteriostatic water or saline with pH buffering agents), preservatives that don't react with the coenzyme structure (benzyl alcohol at 0.9% or lower), and amber glass vials to prevent photodegradation. Mass-market 'NAD+ nasal sprays' often use generic preservatives or insufficiently buffered solutions that accelerate hydrolysis, turning NAD+ into nicotinamide within days of opening.

Small-batch synthesis with exact amino-acid sequencing. The standard we apply across all peptides at Real Peptides. Ensures that the NAD+ delivered in each spray contains the correct adenine-ribose-phosphate-ribose-nicotinamide structure without truncated fragments or isomer contamination. Third-party purity testing verifies molecular weight through HPLC and confirms the absence of bacterial endotoxins, which are common contaminants in lower-grade compounding.

The distinction matters because impure NAD+ doesn't just deliver less benefit. It can trigger inflammatory responses. Endotoxin contamination in peptide formulations activates toll-like receptor 4 (TLR4) pathways, causing systemic inflammation that directly counteracts the metabolic benefits NAD+ is supposed to provide. If you're investing in intranasal NAD+ for research purposes, the formulation quality is as critical as the delivery route.

NAD+ nasal spray isn't a universal longevity solution, but for individuals with confirmed mitochondrial dysfunction or NAD+ depletion, it's the most efficient non-invasive delivery method available. The evidence base is still building, but the pharmacokinetic logic is sound. And unlike oral NAD+, at least the molecule makes it to your cells intact.

References

Peer-reviewed sources on NAD+ indexed in PubMed, listed for research context. Real Peptides supplies NAD+ for laboratory research use only.

NAD⁺ supplementation for anti-aging and wellness: A PRISMA-guided systematic review of preclinical and clinical evidence. Ageing research reviews, 2026. PMID 41655607. doi:10.1016/j.arr.2026.103057
NAD(+) restores proteostasis through splicing-dependent autophagy. Autophagy, 2026. PMID 41313318. doi:10.1080/15548627.2025.2596679
Endothelial NAD(+) depletion drives vascular senescence and neuroinflammation via mtDNA-cGAS/STING-CD38 signaling in Alzheimer's disease. Alzheimer's & dementia : the journal of the Alzheimer's Association, 2026. PMID 42033099. doi:10.1002/alz.71423
NAD+ and Sirt5 restore mitochondrial bioenergetics failure and improve locomotor defects caused by sucla2 mutations. JCI insight, 2026. PMID 41574612. doi:10.1172/jci.insight.181812
NAD(+) depletion drives age-related monocyte hyperinflammation after stroke and is reversed by nicotinamide riboside. Journal of neuroinflammation, 2025. PMID 41299539. doi:10.1186/s12974-025-03638-6
Lactate dehydrogenase A-coupled NAD(+) regeneration is critical for acute myeloid leukemia cell survival. Cancer & metabolism, 2025. PMID 40390151. doi:10.1186/s40170-025-00392-4
FOXO1-NMNAT3 axis dysregulation promotes doxorubicin cardiotoxicity: NAD(+) replenishment as a redox-targeted antioxidant therapy. Redox report : communications in free radical research, 2025. PMID 41021886. doi:10.1080/13510002.2025.2565033
NAD+ prevents chronic kidney disease by activating renal tubular metabolism. JCI insight, 2025. PMID 40059824. doi:10.1172/jci.insight.181443

Build a pack

Researching more than one compound?

Build a multi-vial pack and the discount applies automatically as you add doses.

Start a pack

Questions

NAD+ nasal spray bypasses gastric acid degradation and hepatic first-pass metabolism, delivering the intact coenzyme directly into the bloodstream through the nasal mucosa with 85–90% bioavailability. Oral NAD+ is broken down by stomach acid and liver enzymes into nicotinamide and salvage pathway precursors before reaching systemic circulation, resulting in bioavailability of only 5–15%. Intranasal delivery preserves the NAD+ molecule itself, while oral forms require cellular reconversion through salvage pathways that may be inefficient in NAD+-depleted populations.

Yes, but the combination may be redundant if you’re already responding to NMN or NR supplementation. Intranasal NAD+ delivers the final coenzyme form directly, bypassing the enzymatic conversion step that NMN and NR require through the NAMPT salvage pathway. If you have impaired salvage pathway function or aren’t seeing results from oral precursors, intranasal NAD+ may provide superior benefit. However, if oral precursors are working, adding intranasal NAD+ won’t necessarily increase benefit further — cellular NAD+ uptake has a saturation threshold.

Store unopened NAD+ nasal spray at 2–8°C (refrigerated) in the original amber glass vial to prevent photodegradation. Once opened, use within 30 days and keep refrigerated between uses. NAD+ in solution is stable at room temperature for 24–48 hours but degrades rapidly above 30°C or under direct light exposure. Discard any solution that develops yellow or brown discolouration, as this indicates oxidative degradation of the coenzyme structure. Never freeze NAD+ solutions — ice crystal formation can denature the molecule.

Plasma NAD+ concentrations peak within 15–30 minutes of intranasal administration, with subjective effects (mental clarity, reduced fatigue) typically reported within 30–45 minutes in responsive individuals. The effect is metabolic substrate availability, not acute stimulant activation, so some users may not notice immediate subjective changes. The half-life of intranasally delivered NAD+ is approximately 45–60 minutes, meaning cellular uptake in mitochondria-dense tissues occurs during this window. Consistent daily dosing over 7–10 days provides the most reliable assessment of individual response.

The most common side effects are nasal irritation, mild burning sensation upon administration, or transient sinus discomfort — typically resolving within 5–10 minutes. These are related to osmotic effects of the solution rather than NAD+ itself. Rare adverse events include headache or flushing, likely due to vasodilation from rapid NAD+ influx. There are no documented serious adverse events in published pharmacokinetic studies of intranasal NAD+, but endotoxin contamination in low-quality formulations can trigger inflammatory responses. Always use pharmaceutical-grade, third-party-tested NAD+ to minimise contamination risk.

Intravenous NAD+ achieves 100% bioavailability and immediate plasma concentration, while intranasal delivery achieves 85–90% bioavailability with peak concentrations at 15–30 minutes. The practical difference is minimal for most applications — IV infusions require clinical supervision, sterile technique, and carry risks of infusion site reactions or phlebitis. Intranasal delivery provides nearly equivalent systemic NAD+ levels without medical oversight or injection site complications. Unless you require immediate maximal plasma concentrations (rare outside acute medical settings), intranasal NAD+ offers comparable benefit with far greater practicality.

Research protocols typically use 25–50mg NAD+ per intranasal dose, administered once or twice daily depending on baseline NAD+ status and therapeutic goals. Dosing above 50mg per administration doesn’t proportionally increase absorption — nasal mucosal uptake has a saturation threshold, and excess NAD+ drains into the gastrointestinal tract where it undergoes the same degradation as oral forms. Start at 25mg once daily and assess response over 7–10 days before increasing frequency. Dosing decisions should align with individual metabolic needs, not arbitrary ‘optimisation’ targets.

NAD+ is a required coenzyme for mitochondrial ATP production through the electron transport chain, and intranasal delivery can restore NAD+ levels in mitochondria-dense tissues more efficiently than oral precursors. However, efficacy depends on whether NAD+ depletion is the underlying cause of fatigue. If fatigue is driven by thyroid dysfunction, iron deficiency, or cortisol dysregulation, NAD+ supplementation won’t address the root cause. Whole-blood NAD+/NADH ratio testing can confirm whether NAD+ depletion is present before starting supplementation. For confirmed NAD+ deficiency, intranasal delivery is the most efficient non-invasive restoration method.

Research-grade NAD+ nasal spray uses pharmaceutical-grade solvents, pH-buffered solutions, and third-party purity testing to verify molecular structure and absence of endotoxin contamination. Commercial products often use generic preservatives or insufficiently buffered solutions that accelerate NAD+ hydrolysis into inactive metabolites. Small-batch synthesis with exact amino-acid sequencing ensures the NAD+ molecule retains its adenine-ribose-phosphate-ribose-nicotinamide structure without isomer contamination or truncated fragments. Impure NAD+ doesn’t just deliver reduced benefit — bacterial endotoxins can trigger inflammatory responses that counteract metabolic improvements.

NAD+ itself is not a controlled substance and does not require a prescription in most jurisdictions when sold for research purposes. However, intranasal formulations intended for human therapeutic use may fall under compounding pharmacy regulations or require prescriber oversight depending on state or country-specific laws. Products marketed explicitly for medical treatment (rather than research applications) may be subject to FDA or equivalent regulatory body oversight. Always verify the legal status in your jurisdiction and purchase from suppliers that provide third-party purity verification and transparent sourcing documentation.

RESEARCH USE ONLY · NOT EVALUATED BY THE FDA